Cubist creates chief medical officer
Executive Summary
Cubist names William Pullman senior VP & chief medical officer. The exec has an extensive development background, having worked for Pfizer, Lilly, Sanofi-Aventis and most recently with TransForm Pharmaceuticals. Cubist recently expanded the label of its flagship antibiotic Cubicin to include a Staph aureus bacteremia indication. Pullman is expected to assist in building the company's pipeline, which includes its Phase II monoclonal antibody combination product HepeX-B...
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.